Export

Glecaprevir + pibrentasvir
Essential medicine status
General description

INN
Glecaprevir + pibrentasvir
Medicine type
Chemical agent
EML status history
First added in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
  • Oral > Solid: 100 mg + 40 mg tablet